147 related articles for article (PubMed ID: 34873470)
1. CD11b
Kudo-Saito C; Ogiwara Y; Imazeki H; Boku N; Uemura Y; Zhang R; Kawano-Nagatsuma A; Kojima M; Ochiai A
Am J Cancer Res; 2021; 11(11):5428-5439. PubMed ID: 34873470
[TBL] [Abstract][Full Text] [Related]
2. CD11b
Imazeki H; Ogiwara Y; Kawamura M; Boku N; Kudo-Saito C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34261702
[TBL] [Abstract][Full Text] [Related]
3. Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.
Kudo-Saito C; Ishida A; Shouya Y; Teramoto K; Igarashi T; Kon R; Saito K; Awada C; Ogiwara Y; Toyoura M
Cell Rep; 2018 Aug; 24(7):1790-1801. PubMed ID: 30110636
[TBL] [Abstract][Full Text] [Related]
4. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
Ogiwara Y; Nakagawa M; Nakatani F; Uemura Y; Zhang R; Kudo-Saito C
Cancer Lett; 2022 Jul; 537():215690. PubMed ID: 35439537
[TBL] [Abstract][Full Text] [Related]
5. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
[No Abstract] [Full Text] [Related]
6. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
[TBL] [Abstract][Full Text] [Related]
7. Dynamic resistance exercise increases skeletal muscle-derived FSTL1 inducing cardiac angiogenesis via DIP2A-Smad2/3 in rats following myocardial infarction.
Xi Y; Hao M; Liang Q; Li Y; Gong DW; Tian Z
J Sport Health Sci; 2021 Sep; 10(5):594-603. PubMed ID: 33246164
[TBL] [Abstract][Full Text] [Related]
8. Follistatin-like 1 attenuates apoptosis via disco-interacting protein 2 homolog A/Akt pathway after middle cerebral artery occlusion in rats.
Liang X; Hu Q; Li B; McBride D; Bian H; Spagnoli P; Chen D; Tang J; Zhang JH
Stroke; 2014 Oct; 45(10):3048-3054. PubMed ID: 25139876
[TBL] [Abstract][Full Text] [Related]
9. Determination of follistatin-like protein 1 expression in colorectal cancer and its association with clinical outcomes.
Zhao Y; Ou Q; Deng Y; Peng J; Li C; Li J; Zhao Q; Qiu M; Wan D; Fang Y; Pan Z
Ann Transl Med; 2019 Nov; 7(21):606. PubMed ID: 32047767
[TBL] [Abstract][Full Text] [Related]
10. DIP2A functions as a FSTL1 receptor.
Ouchi N; Asaumi Y; Ohashi K; Higuchi A; Sono-Romanelli S; Oshima Y; Walsh K
J Biol Chem; 2010 Mar; 285(10):7127-34. PubMed ID: 20054002
[TBL] [Abstract][Full Text] [Related]
11. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway.
Gu C; Wang X; Long T; Wang X; Zhong Y; Ma Y; Hu Z; Li Z
Cell Death Dis; 2018 May; 9(6):654. PubMed ID: 29844309
[TBL] [Abstract][Full Text] [Related]
12. Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer.
Ozawa H; Imazeki H; Ogiwara Y; Kawakubo H; Fukuda K; Kitagawa Y; Kudo-Saito C
Transl Oncol; 2022 Feb; 16():101307. PubMed ID: 34902741
[TBL] [Abstract][Full Text] [Related]
13. Follistatin-like protein 1 sustains colon cancer cell growth and survival.
Bevivino G; Sedda S; Franzè E; Stolfi C; Di Grazia A; Dinallo V; Caprioli F; Facciotti F; Colantoni A; Ortenzi A; Rossi P; Monteleone G
Oncotarget; 2018 Jul; 9(58):31278-31290. PubMed ID: 30131854
[TBL] [Abstract][Full Text] [Related]
14. Astragalus polysaccharide ameliorates CD8
Li Q; Zhang C; Xu G; Shang X; Nan X; Li Y; Liu J; Hong Y; Wang Q; Peng G
Biomed Pharmacother; 2024 Feb; 171():116172. PubMed ID: 38278025
[TBL] [Abstract][Full Text] [Related]
15. Follistatin-like 1 is a myokine regulating lipid mobilization during endurance exercise and recovery.
Nam JS; Park SJ; Ahn CW; Cho ES; Kim HJ; Kim Y
Obesity (Silver Spring); 2024 Feb; 32(2):352-362. PubMed ID: 38018497
[TBL] [Abstract][Full Text] [Related]
16. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
17. CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.
Oshima K; Shoji H; Boku N; Hirano H; Okita N; Takashima A; Kato K; Kudo-Saito C
Am J Cancer Res; 2024; 14(3):1174-1189. PubMed ID: 38590413
[TBL] [Abstract][Full Text] [Related]
18. Targeting FSTL1 prevents tumor bone metastasis and consequent immune dysfunction.
Kudo-Saito C; Fuwa T; Murakami K; Kawakami Y
Cancer Res; 2013 Oct; 73(20):6185-93. PubMed ID: 23966294
[TBL] [Abstract][Full Text] [Related]
19. IL25
Ozaki Y; Kinowaki K; Kawabata H; Kudo-Saito C
Am J Cancer Res; 2023; 13(10):4931-4943. PubMed ID: 37970362
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma.
Zhou X; Xiao X; Huang T; Du C; Wang S; Mo Y; Ma N; Murata M; Li B; Wen W; Huang G; Zeng X; Zhang Z
Oncotarget; 2016 Mar; 7(13):16433-44. PubMed ID: 26918942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
